Antitope Announces Protein Deimmunisation Research Agreement With NeuroPhage Pharmaceuticals, Inc.
"We are delighted to be working with such an innovative company as NeuroPhage," said Dr Matthew Baker, Chief Executive Officer and co-founder of Antitope, adding "This partnership utilises Antitope's expertise in engineering non-immunogenic proteins to complement NeuroPhage's innovations in developing novel therapeutics based on clearance of pathological protein aggregates."
About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of proteins and humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
For more information, please visit www.antitope.co.uk.or contact:
Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190
Emai: info@antitope.co.uk
About NeuroPhage Parmaceuticals, Inc.
NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA, USA, along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.
For more information, please visit www.neurophage.com or contact info@neurophage.com